Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/38097
Title: The Efficacy of Bismuth based Quadruple and Sequential Therapies in Helicobacter pylori Eradication
Authors: Coskun, A
Çelik, Mustafa
Kandemir, A
Keywords: Helicobacter pylori; quadruple treatment; sequential treatment
Publisher: GALENOS YAYINCILIK
Abstract: Objective: New therapy regimens are needed for Helicobacter pylori H. pylori) eradication because of increased resistance to the commonly used antibiotics. This study aimed to compare the efficacy of bismuth quadruple therapy versus sequential therapy for H. pylori eradication.
Materials and Methods: Patients who presented with dyspepsia complaints and were diagnosed with H. pylori infection by histopathologic examination of biopsies obtained by gastroscopy were evaluated retrospectively. Two hundred and five patients who received bismuth-based quadruple therapy and sequential therapy for H. pylori eradication were included in the study. Bismuth-based quadruple therapy group were given pantoprazole 2x40 mg, bismuth subcitrate 4x300 mg, amoxicillin 2x1000 mg and metronidazole 3x500 mg for 14 days. In the bismuth-based sequential therapy group, the protocol was as follows; pantoprazole 2x40 mg (14 days), bismuth subcitrate 4x300 mg (14 days), amoxicillin 2x1000 mg (first 7 days), metronidazole 3x500 mg (second 7 days) and levofloxacin 1x500 mg (second 7 days). Eradication was determined by stool H. pylori Antigen test six weeks after the treatment.
Results: A total of 102 patients in group 1 and 91 patients in group 2 completed the treatment and there was no significant difference between the two groups (p=0.310). H. pylori eradication rate showed no significant difference between the two groups (p=0.093), while group 1 attained a better eradication rate than group 2 on intention-to-treat, which was statistically significant (p=0.033).
Conclusion: We achieved better eradication rates with bismuth-based quadruple therapy compared to the sequential therapy. We recommend bismuth-based quadruple regimen as the first-line eradication therapy to avoid drug incompatabilities seen during the sequential regime.
URI: https://hdl.handle.net/11499/38097
https://doi.org/10.4274/meandros.galenos.2019.08831
ISSN: 2149-9063
Appears in Collections:Tıp Fakültesi Koleksiyonu
TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
d34a3be7-349c-42d1-b631-ba5393fcee74.pdf311.77 kBAdobe PDFView/Open
Show full item record



CORE Recommender

Page view(s)

80
checked on Aug 24, 2024

Download(s)

18
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.